English
简体中文
Total: £ 56.28
Published Date: 2026-01-13 | Pages: 112 | Tables: 117 | Pharma & Healthcare
The global Urokinase market was valued at US$ 82.09 million in 2025 and is anticipated to reach US$ 120 million by 2032, at a CAGR of 5.2% from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Urokinase competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Urokinase is a clot-dissolving medicine. It is a natural enzyme (a protein) that activates the body’s own fibrinolytic system by converting plasminogen into plasmin, and plasmin then breaks down fibrin, which is the “mesh” that holds a blood clot together. This is why urokinase is called a thrombolytic or “clot-buster.” The market for urokinase mainly includes injectable products (usually a sterile powder that is dissolved before use) that are given in hospitals, either through a vein or through a catheter directly to the clot area, depending on the indication and local practice. The clinical risk that shapes this market is also simple: because the drug dissolves clots, it can also weaken normal clotting at injury sites, so bleeding is the key safety concern and a major reason urokinase is used in controlled hospital settings.
A practical market definition should also include how urokinase is made, because that affects supply, regulatory burden, and cost. Urokinase products can differ by source. The U.S. Kinlytic label describes production from human neonatal kidney cells grown in tissue culture, and it explains extensive donor screening and virus testing/inactivation steps because it is derived from human source material. In contrast, some European product information describes urokinase that is extracted from human urine. These differences matter commercially: biologic sourcing and validation requirements make it harder for many manufacturers to enter, and they increase the importance of quality systems, change control, and reliable supply chains.
On the demand side, the most basic driver is that blood clots are common, and a subset of them are severe enough that rapid clot removal is lifesaving or limb-saving. The U.S. CDC says up to 900,000 people in the United States are affected by venous thromboembolism (VTE) each year, and VTE is linked to tens of thousands of deaths. Globally, cardiovascular diseases are still the leading cause of death, and they overlap with clot problems and high-risk hospital populations. These facts do not mean every clot patient needs urokinase. Most patients receive anticoagulants and supportive care, not thrombolytics. But they explain why hospitals continue to need a set of clot-management tools, including thrombolytic drugs, for the most urgent cases.
In 2025, global Urokinase production reached approximately 2736 BIU, with an average global market price of around US$ 30 per MIU. The global single-line production capacity ranges from 100 to 150 BIU per year. The industry's gross profit margin is approximately 25%-35%.
One of the clearest growth “pockets” for urokinase is catheter and access-device management. Modern medicine uses a large volume of central venous catheters for chemotherapy, nutrition, antibiotics, and dialysis. These devices can become blocked by thrombus or fibrin sheaths. In Europe, regulatory summaries describe urokinase use for clots in catheters or cannulae, which is essentially “catheter clearance.” Clinical literature on thrombolytic therapy for catheter occlusion discusses multiple agents and reports that thrombolytics can restore patency in a meaningful share of blocked catheters, with performance differences by drug and dosing strategy; this is a major reason hospitals keep thrombolytic protocols for catheter salvage. When catheter salvage works, it avoids line replacement, reduces procedure risk, and helps preserve access sites—especially important for dialysis and oncology patients. This clinical logic is also why companies publicly frame catheter clearance as an attractive commercial segment when they talk about bringing urokinase products back to market.
A second demand segment is catheter-directed thrombolysis (CDT) for limb-threatening peripheral arterial occlusion or extensive venous thrombosis, where drug is infused locally through a catheter rather than given as a full systemic infusion. Product information for urokinase in Europe explicitly describes acute peripheral arterial occlusions and notes that catheter-directed local lysis is the preferred method of administration for that scenario. More recent reviews also describe CDT as an effective endovascular method for thrombotic peripheral artery occlusions, while emphasizing the need for careful monitoring because bleeding and other complications are real. This creates a steady, procedure-linked demand for urokinase (and competing thrombolytics) in hospitals that perform vascular interventions. The market driver here is not only disease incidence; it is the expansion of interventional capability, better imaging, and more hospitals building vascular teams that can do “minimally invasive” clot removal rather than open surgery in selected patients.
At the same time, a major market trend is that urokinase is not the only clot-buster, and in some very large indications it has been replaced by other approaches. In acute ischemic stroke, for example, many regions use alteplase or tenecteplase, and mechanical thrombectomy has grown for large-vessel occlusions. In myocardial infarction, primary PCI has replaced thrombolysis in many systems where rapid catheterization is available. These shifts matter because they move thrombolytic use toward more specialized niches. In catheter clearance specifically, alteplase has strong clinical adoption in many settings, and reviews discuss its clearance rates and how other agents compare. So, one trend in the urokinase market is “narrower but deeper”: fewer broad, mass-market indications, but ongoing need in hospital procedures and device-related clots where protocols and economics favor certain agents.
Global key players of urokinase include Syner-Med, LIVZON, Wanhua Biochem, etc. The top three players hold a share about 50%.
This report delivers a comprehensive overview of the global Urokinase market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Urokinase. The Urokinase market size, estimates, and forecasts are provided in terms of sales volume (BIU) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Urokinase market comprehensively. Regional market sizes by Type, by Application, by Clinical Use, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Urokinase manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Syner-Med
Wanhua Biochem
Jiangxi Haoran Bio-Pharma
Jiangsu Aidea Pharmaceutical
Techpool
Microbic Biosystems
LIVZON
Wuhan Humanwell Pharma
Tianjin Biochem Pharma
Segment by Type
Urokinase Powder
Urokinase Solution
Segment by Clinical Use
Pulmonary Embolism Thrombolysis
Deep Vein Thrombosis
Peripheral Arterial Occlusion Thrombolysis
Catheter / Cannula Occlusion Clearance
Others
Segment by Administration Approach
Systemic Infusion
Catheter-directed Thrombolysis (CDT)
Intracatheter Dwell / Lock Technique
Segment by Purity
Standard Clinical Grade
High-purity / Low-impurity Grade
Low Endotoxin / Low Bioburden Specifications
by Application
Hospital
Clinic
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Clinical Use, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Urokinase manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Urokinase sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Urokinase Market Overview
1.1 Product Definition
1.2 Urokinase by Type
1.2.1 Global Urokinase Market Value by Type: 2025 vs 2032
1.2.2 Urokinase Powder
1.2.3 Urokinase Solution
1.3 Urokinase by Clinical Use
1.3.1 Global Urokinase Market Value by Clinical Use: 2025 vs 2032
1.3.2 Pulmonary Embolism Thrombolysis
1.3.3 Deep Vein Thrombosis
1.3.4 Peripheral Arterial Occlusion Thrombolysis
1.3.5 Catheter / Cannula Occlusion Clearance
1.3.6 Others
1.4 Urokinase by Administration Approach
1.4.1 Global Urokinase Market Value by Administration Approach: 2025 vs 2032
1.4.2 Systemic Infusion
1.4.3 Catheter-directed Thrombolysis (CDT)
1.4.4 Intracatheter Dwell / Lock Technique
1.5 Urokinase by Purity
1.5.1 Global Urokinase Market Value by Purity: 2025 vs 2032
1.5.2 Standard Clinical Grade
1.5.3 High-purity / Low-impurity Grade
1.5.4 Low Endotoxin / Low Bioburden Specifications
1.6 Urokinase by Application
1.6.1 Global Urokinase Market Value by Application: 2025 vs 2032
1.6.2 Hospital
1.6.3 Clinic
1.6.4 Others
1.7 Global Urokinase Market Size Estimates and Forecasts
1.7.1 Global Urokinase Revenue 2021–2032
1.7.2 Global Urokinase Sales 2021–2032
1.7.3 Global Urokinase Market Average Price (2021–2032)
1.8 Assumptions and Limitations
2 Urokinase Market Competition by Manufacturers
2.1 Global Urokinase Sales Market Share by Manufacturers (2021–2026)
2.2 Global Urokinase Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Urokinase Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Urokinase, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Urokinase, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Urokinase, Product Types and Applications
2.7 Global Key Manufacturers of Urokinase, Date of Entry into the Industry
2.8 Global Urokinase Market Competitive Situation and Trends
2.8.1 Global Urokinase Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Urokinase Players Market Share by Revenue
2.8.3 Global Urokinase Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Urokinase Market Scenario by Region
3.1 Global Urokinase Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Urokinase Sales by Region: 2021–2032
3.2.1 Global Urokinase Sales by Region: 2021–2026
3.2.2 Global Urokinase Sales by Region: 2027–2032
3.3 Global Urokinase Revenue by Region: 2021–2032
3.3.1 Global Urokinase Revenue by Region: 2021–2026
3.3.2 Global Urokinase Revenue by Region: 2027–2032
3.4 North America Urokinase Market Facts & Figures by Country
3.4.1 North America Urokinase Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Urokinase Sales by Country (2021–2032)
3.4.3 North America Urokinase Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Urokinase Market Facts & Figures by Country
3.5.1 Europe Urokinase Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Urokinase Sales by Country (2021–2032)
3.5.3 Europe Urokinase Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Urokinase Market Facts & Figures by Region
3.6.1 Asia Pacific Urokinase Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Urokinase Sales by Region (2021–2032)
3.6.3 Asia Pacific Urokinase Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Urokinase Market Facts & Figures by Country
3.7.1 Latin America Urokinase Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Urokinase Sales by Country (2021–2032)
3.7.3 Latin America Urokinase Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Urokinase Market Facts & Figures by Country
3.8.1 Middle East and Africa Urokinase Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Urokinase Sales by Country (2021–2032)
3.8.3 Middle East and Africa Urokinase Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Urokinase Sales by Type (2021–2032)
4.1.1 Global Urokinase Sales by Type (2021–2026)
4.1.2 Global Urokinase Sales by Type (2027–2032)
4.1.3 Global Urokinase Sales Market Share by Type (2021–2032)
4.2 Global Urokinase Revenue by Type (2021–2032)
4.2.1 Global Urokinase Revenue by Type (2021–2026)
4.2.2 Global Urokinase Revenue by Type (2027–2032)
4.2.3 Global Urokinase Revenue Market Share by Type (2021–2032)
4.3 Global Urokinase Price by Type (2021–2032)
5 Segment by Application
5.1 Global Urokinase Sales by Application (2021–2032)
5.1.1 Global Urokinase Sales by Application (2021–2026)
5.1.2 Global Urokinase Sales by Application (2027–2032)
5.1.3 Global Urokinase Sales Market Share by Application (2021–2032)
5.2 Global Urokinase Revenue by Application (2021–2032)
5.2.1 Global Urokinase Revenue by Application (2021–2026)
5.2.2 Global Urokinase Revenue by Application (2027–2032)
5.2.3 Global Urokinase Revenue Market Share by Application (2021–2032)
5.3 Global Urokinase Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Syner-Med
6.1.1 Syner-Med Company Information
6.1.2 Syner-Med Description and Business Overview
6.1.3 Syner-Med Urokinase Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Syner-Med Urokinase Product Portfolio
6.1.5 Syner-Med Recent Developments/Updates
6.2 Wanhua Biochem
6.2.1 Wanhua Biochem Company Information
6.2.2 Wanhua Biochem Description and Business Overview
6.2.3 Wanhua Biochem Urokinase Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Wanhua Biochem Urokinase Product Portfolio
6.2.5 Wanhua Biochem Recent Developments/Updates
6.3 Jiangxi Haoran Bio-Pharma
6.3.1 Jiangxi Haoran Bio-Pharma Company Information
6.3.2 Jiangxi Haoran Bio-Pharma Description and Business Overview
6.3.3 Jiangxi Haoran Bio-Pharma Urokinase Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Jiangxi Haoran Bio-Pharma Urokinase Product Portfolio
6.3.5 Jiangxi Haoran Bio-Pharma Recent Developments/Updates
6.4 Jiangsu Aidea Pharmaceutical
6.4.1 Jiangsu Aidea Pharmaceutical Company Information
6.4.2 Jiangsu Aidea Pharmaceutical Description and Business Overview
6.4.3 Jiangsu Aidea Pharmaceutical Urokinase Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Jiangsu Aidea Pharmaceutical Urokinase Product Portfolio
6.4.5 Jiangsu Aidea Pharmaceutical Recent Developments/Updates
6.5 Techpool
6.5.1 Techpool Company Information
6.5.2 Techpool Description and Business Overview
6.5.3 Techpool Urokinase Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Techpool Urokinase Product Portfolio
6.5.5 Techpool Recent Developments/Updates
6.6 Microbic Biosystems
6.6.1 Microbic Biosystems Company Information
6.6.2 Microbic Biosystems Description and Business Overview
6.6.3 Microbic Biosystems Urokinase Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Microbic Biosystems Urokinase Product Portfolio
6.6.5 Microbic Biosystems Recent Developments/Updates
6.7 LIVZON
6.7.1 LIVZON Company Information
6.7.2 LIVZON Description and Business Overview
6.7.3 LIVZON Urokinase Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 LIVZON Urokinase Product Portfolio
6.7.5 LIVZON Recent Developments/Updates
6.8 Wuhan Humanwell Pharma
6.8.1 Wuhan Humanwell Pharma Company Information
6.8.2 Wuhan Humanwell Pharma Description and Business Overview
6.8.3 Wuhan Humanwell Pharma Urokinase Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Wuhan Humanwell Pharma Urokinase Product Portfolio
6.8.5 Wuhan Humanwell Pharma Recent Developments/Updates
6.9 Tianjin Biochem Pharma
6.9.1 Tianjin Biochem Pharma Company Information
6.9.2 Tianjin Biochem Pharma Description and Business Overview
6.9.3 Tianjin Biochem Pharma Urokinase Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Tianjin Biochem Pharma Urokinase Product Portfolio
6.9.5 Tianjin Biochem Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Urokinase Industry Chain Analysis
7.2 Urokinase Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Urokinase Production Mode & Process Analysis
7.4 Urokinase Sales and Marketing
7.4.1 Urokinase Sales Channels
7.4.2 Urokinase Distributors
7.5 Urokinase Customer Analysis
8 Urokinase Market Dynamics
8.1 Urokinase Industry Trends
8.2 Urokinase Market Drivers
8.3 Urokinase Market Challenges
8.4 Urokinase Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Urokinase Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Urokinase Market Value by Clinical Use (US$ Million), 2025 vs 2032
Table 3. Global Urokinase Market Value by Administration Approach (US$ Million), 2025 vs 2032
Table 4. Global Urokinase Market Value by Purity (US$ Million), 2025 vs 2032
Table 5. Global Urokinase Market Value by Application (US$ Million), 2025 vs 2032
Table 6. Global Urokinase Market Competitive Situation by Manufacturers in 2025
Table 7. Global Urokinase Sales (BIU) of Key Manufacturers (2021–2026)
Table 8. Global Urokinase Sales Market Share by Manufacturers (2021–2026)
Table 9. Global Urokinase Revenue (US$ Million) by Manufacturers (2021–2026)
Table 10. Global Urokinase Revenue Share by Manufacturers (2021–2026)
Table 11. Global Market Urokinase Average Price (US$/MIU) of Key Manufacturers (2021–2026)
Table 12. Global Key Players of Urokinase, Industry Ranking, 2023 vs 2024 vs 2025
Table 13. Global Key Manufacturers of Urokinase, Manufacturing Sites and Headquarters
Table 14. Global Key Manufacturers of Urokinase, Product Types and Applications
Table 15. Global Key Manufacturers of Urokinase, Date of Entry into the Industry
Table 16. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Urokinase Companies by Tier (Tier 1, Tier 2, Tier 3), based on Urokinase Revenue, 2025
Table 18. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 19. Global Urokinase Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 20. Global Urokinase Sales by Region (BIU), 2021–2026
Table 21. Global Urokinase Sales Market Share by Region (2021–2026)
Table 22. Global Urokinase Sales by Region (BIU), 2027–2032
Table 23. Global Urokinase Sales Market Share by Region (2027–2032)
Table 24. Global Urokinase Revenue by Region (US$ Million), 2021–2026
Table 25. Global Urokinase Revenue Market Share by Region (2021–2026)
Table 26. Global Urokinase Revenue by Region (US$ Million), 2027–2032
Table 27. Global Urokinase Revenue Market Share by Region (2027–2032)
Table 28. North America Urokinase Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 29. North America Urokinase Sales by Country (BIU), 2021–2026
Table 30. North America Urokinase Sales by Country (BIU), 2027–2032
Table 31. North America Urokinase Revenue by Country (US$ Million), 2021–2026
Table 32. North America Urokinase Revenue by Country (US$ Million), 2027–2032
Table 33. Europe Urokinase Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Europe Urokinase Sales by Country (BIU), 2021–2026
Table 35. Europe Urokinase Sales by Country (BIU), 2027–2032
Table 36. Europe Urokinase Revenue by Country (US$ Million), 2021–2026
Table 37. Europe Urokinase Revenue by Country (US$ Million), 2027–2032
Table 38. Asia Pacific Urokinase Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 39. Asia Pacific Urokinase Sales by Region (BIU), 2021–2026
Table 40. Asia Pacific Urokinase Sales by Region (BIU), 2027–2032
Table 41. Asia Pacific Urokinase Revenue by Region (US$ Million), 2021–2026
Table 42. Asia Pacific Urokinase Revenue by Region (US$ Million), 2027–2032
Table 43. Latin America Urokinase Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 44. Latin America Urokinase Sales by Country (BIU), 2021–2026
Table 45. Latin America Urokinase Sales by Country (BIU), 2027–2032
Table 46. Latin America Urokinase Revenue by Country (US$ Million), 2021–2026
Table 47. Latin America Urokinase Revenue by Country (US$ Million), 2027–2032
Table 48. Middle East and Africa Urokinase Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 49. Middle East and Africa Urokinase Sales by Country (BIU), 2021–2026
Table 50. Middle East and Africa Urokinase Sales by Country (BIU), 2027–2032
Table 51. Middle East and Africa Urokinase Revenue by Country (US$ Million), 2021–2026
Table 52. Middle East and Africa Urokinase Revenue by Country (US$ Million), 2027–2032
Table 53. Global Urokinase Sales (BIU) by Type (2021–2026)
Table 54. Global Urokinase Sales (BIU) by Type (2027–2032)
Table 55. Global Urokinase Sales Market Share by Type (2021–2026)
Table 56. Global Urokinase Sales Market Share by Type (2027–2032)
Table 57. Global Urokinase Revenue (US$ Million) by Type (2021–2026)
Table 58. Global Urokinase Revenue (US$ Million) by Type (2027–2032)
Table 59. Global Urokinase Revenue Market Share by Type (2021–2026)
Table 60. Global Urokinase Revenue Market Share by Type (2027–2032)
Table 61. Global Urokinase Price (US$/MIU) by Type (2021–2026)
Table 62. Global Urokinase Price (US$/MIU) by Type (2027–2032)
Table 63. Global Urokinase Sales (BIU) by Application (2021–2026)
Table 64. Global Urokinase Sales (BIU) by Application (2027–2032)
Table 65. Global Urokinase Sales Market Share by Application (2021–2026)
Table 66. Global Urokinase Sales Market Share by Application (2027–2032)
Table 67. Global Urokinase Revenue (US$ Million) by Application (2021–2026)
Table 68. Global Urokinase Revenue (US$ Million) by Application (2027–2032)
Table 69. Global Urokinase Revenue Market Share by Application (2021–2026)
Table 70. Global Urokinase Revenue Market Share by Application (2027–2032)
Table 71. Global Urokinase Price (US$/MIU) by Application (2021–2026)
Table 72. Global Urokinase Price (US$/MIU) by Application (2027–2032)
Table 73. Syner-Med Company Information
Table 74. Syner-Med Description and Business Overview
Table 75. Syner-Med Urokinase Sales (BIU), Revenue (US$ Million), Price (US$/MIU), and Gross Margin (2021–2026)
Table 76. Syner-Med Urokinase Product
Table 77. Syner-Med Recent Developments/Updates
Table 78. Wanhua Biochem Company Information
Table 79. Wanhua Biochem Description and Business Overview
Table 80. Wanhua Biochem Urokinase Sales (BIU), Revenue (US$ Million), Price (US$/MIU), and Gross Margin (2021–2026)
Table 81. Wanhua Biochem Urokinase Product
Table 82. Wanhua Biochem Recent Developments/Updates
Table 83. Jiangxi Haoran Bio-Pharma Company Information
Table 84. Jiangxi Haoran Bio-Pharma Description and Business Overview
Table 85. Jiangxi Haoran Bio-Pharma Urokinase Sales (BIU), Revenue (US$ Million), Price (US$/MIU), and Gross Margin (2021–2026)
Table 86. Jiangxi Haoran Bio-Pharma Urokinase Product
Table 87. Jiangxi Haoran Bio-Pharma Recent Developments/Updates
Table 88. Jiangsu Aidea Pharmaceutical Company Information
Table 89. Jiangsu Aidea Pharmaceutical Description and Business Overview
Table 90. Jiangsu Aidea Pharmaceutical Urokinase Sales (BIU), Revenue (US$ Million), Price (US$/MIU), and Gross Margin (2021–2026)
Table 91. Jiangsu Aidea Pharmaceutical Urokinase Product
Table 92. Jiangsu Aidea Pharmaceutical Recent Developments/Updates
Table 93. Techpool Company Information
Table 94. Techpool Description and Business Overview
Table 95. Techpool Urokinase Sales (BIU), Revenue (US$ Million), Price (US$/MIU), and Gross Margin (2021–2026)
Table 96. Techpool Urokinase Product
Table 97. Techpool Recent Developments/Updates
Table 98. Microbic Biosystems Company Information
Table 99. Microbic Biosystems Description and Business Overview
Table 100. Microbic Biosystems Urokinase Sales (BIU), Revenue (US$ Million), Price (US$/MIU), and Gross Margin (2021–2026)
Table 101. Microbic Biosystems Urokinase Product
Table 102. Microbic Biosystems Recent Developments/Updates
Table 103. LIVZON Company Information
Table 104. LIVZON Description and Business Overview
Table 105. LIVZON Urokinase Sales (BIU), Revenue (US$ Million), Price (US$/MIU), and Gross Margin (2021–2026)
Table 106. LIVZON Urokinase Product
Table 107. LIVZON Recent Developments/Updates
Table 108. Wuhan Humanwell Pharma Company Information
Table 109. Wuhan Humanwell Pharma Description and Business Overview
Table 110. Wuhan Humanwell Pharma Urokinase Sales (BIU), Revenue (US$ Million), Price (US$/MIU), and Gross Margin (2021–2026)
Table 111. Wuhan Humanwell Pharma Urokinase Product
Table 112. Wuhan Humanwell Pharma Recent Developments/Updates
Table 113. Tianjin Biochem Pharma Company Information
Table 114. Tianjin Biochem Pharma Description and Business Overview
Table 115. Tianjin Biochem Pharma Urokinase Sales (BIU), Revenue (US$ Million), Price (US$/MIU), and Gross Margin (2021–2026)
Table 116. Tianjin Biochem Pharma Urokinase Product
Table 117. Tianjin Biochem Pharma Recent Developments/Updates
Table 118. Key Raw Materials Lists
Table 119. Raw Materials Key Suppliers Lists
Table 120. Urokinase Distributors List
Table 121. Urokinase Customers List
Table 122. Urokinase Market Trends
Table 123. Urokinase Market Drivers
Table 124. Urokinase Market Challenges
Table 125. Urokinase Market Restraints
Table 126. Research Programs/Design for This Report
Table 127. Key Data Information from Secondary Sources
Table 128. Key Data Information from Primary Sources
Table 129. Authors List of This Report
List of Figures
Figure 1. Product Picture of Urokinase
Figure 2. Global Urokinase Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Urokinase Market Share by Type: 2025 & 2032
Figure 4. Urokinase Powder Product Picture
Figure 5. Urokinase Solution Product Picture
Figure 6. Global Urokinase Market Value by Clinical Use (US$ Million), 2021–2032
Figure 7. Global Urokinase Market Share by Clinical Use: 2025 vs 2032
Figure 8. Pulmonary Embolism Thrombolysis Product Picture
Figure 9. Deep Vein Thrombosis Product Picture
Figure 10. Peripheral Arterial Occlusion Thrombolysis Product Picture
Figure 11. Catheter / Cannula Occlusion Clearance Product Picture
Figure 12. Others Product Picture
Figure 13. Global Urokinase Market Value by Administration Approach (US$ Million), 2021–2032
Figure 14. Global Urokinase Market Share by Administration Approach: 2025 vs 2032
Figure 15. Systemic Infusion Product Picture
Figure 16. Catheter-directed Thrombolysis (CDT) Product Picture
Figure 17. Intracatheter Dwell / Lock Technique Product Picture
Figure 18. Global Urokinase Market Value by Purity (US$ Million), 2021–2032
Figure 19. Global Urokinase Market Share by Purity: 2025 vs 2032
Figure 20. Standard Clinical Grade Product Picture
Figure 21. High-purity / Low-impurity Grade Product Picture
Figure 22. Low Endotoxin / Low Bioburden Specifications Product Picture
Figure 23. Global Urokinase Market Value by Application (US$ Million), 2021–2032
Figure 24. Global Urokinase Market Share by Application: 2025 & 2032
Figure 25. Hospital
Figure 26. Clinic
Figure 27. Others
Figure 28. Global Urokinase Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 29. Global Urokinase Market Size (US$ Million), 2021–2032
Figure 30. Global Urokinase Sales (BIU), 2021–2032
Figure 31. Global Urokinase Average Price (US$/MIU), 2021–2032
Figure 32. Urokinase Report Years Considered
Figure 33. Urokinase Sales Share by Manufacturers in 2025
Figure 34. Global Urokinase Revenue Share by Manufacturers in 2025
Figure 35. Top 5 and Top 10 Global Urokinase Players: Market Share by Revenue in Urokinase in 2025
Figure 36. Urokinase Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 37. Global Urokinase Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 38. North America Urokinase Sales Market Share by Country (2021–2032)
Figure 39. North America Urokinase Revenue Market Share by Country (2021–2032)
Figure 40. United States Urokinase Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Canada Urokinase Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Europe Urokinase Sales Market Share by Country (2021–2032)
Figure 43. Europe Urokinase Revenue Market Share by Country (2021–2032)
Figure 44. Germany Urokinase Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. France Urokinase Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. U.K. Urokinase Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Italy Urokinase Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Russia Urokinase Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Asia Pacific Urokinase Sales Market Share by Region (2021–2032)
Figure 50. Asia Pacific Urokinase Revenue Market Share by Region (2021–2032)
Figure 51. China Urokinase Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Japan Urokinase Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. South Korea Urokinase Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. India Urokinase Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. Australia Urokinase Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. China Taiwan Urokinase Revenue Growth Rate (US$ Million), 2021–2032
Figure 57. Indonesia Urokinase Revenue Growth Rate (US$ Million), 2021–2032
Figure 58. Thailand Urokinase Revenue Growth Rate (US$ Million), 2021–2032
Figure 59. Malaysia Urokinase Revenue Growth Rate (US$ Million), 2021–2032
Figure 60. Latin America Urokinase Sales Market Share by Country (2021–2032)
Figure 61. Latin America Urokinase Revenue Market Share by Country (2021–2032)
Figure 62. Mexico Urokinase Revenue Growth Rate (US$ Million), 2021–2032
Figure 63. Brazil Urokinase Revenue Growth Rate (US$ Million), 2021–2032
Figure 64. Argentina Urokinase Revenue Growth Rate (US$ Million), 2021–2032
Figure 65. Middle East and Africa Urokinase Sales Market Share by Country (2021–2032)
Figure 66. Middle East and Africa Urokinase Revenue Market Share by Country (2021–2032)
Figure 67. Turkey Urokinase Revenue Growth Rate (US$ Million), 2021–2032
Figure 68. Saudi Arabia Urokinase Revenue Growth Rate (US$ Million), 2021–2032
Figure 69. UAE Urokinase Revenue Growth Rate (US$ Million), 2021–2032
Figure 70. Global Sales Market Share of Urokinase by Type (2021–2032)
Figure 71. Global Revenue Market Share of Urokinase by Type (2021–2032)
Figure 72. Global Urokinase Price (US$/MIU) by Type (2021–2032)
Figure 73. Global Sales Market Share of Urokinase by Application (2021–2032)
Figure 74. Global Revenue Market Share of Urokinase by Application (2021–2032)
Figure 75. Global Urokinase Price (US$/MIU) by Application (2021–2032)
Figure 76. Urokinase Value Chain
Figure 77. Channels of Distribution (Direct Vs Distribution)
Figure 78. Bottom-up and Top-down Approaches for This Report
Figure 79. Data Triangulation
Figure 80. Key Executives Interviewed
